MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/jcm15187323

Медицинская библиотека · Journal of clinical medicine · 2026

Efficacy and Safety of Response-Adapted Intravitreal Methotrexate Therapy for Vitreoretinal Lymphoma: A Two-Center Retrospective Cohort Study.

Cioboată Mihai-Luca, Tofolean Ioana, Abduraman Suher, Burcea Radu, Chiotan-Călin Maria-Alexandra, Chiotan Radu-Alexandru, Dăscălescu Dana-Margareta-Cornelia, Cioboată Miruna, Çelebi Ali Rıza Cenk, Baltă Florian

СтатьяПеревод в очереди

Аннотация

Objectives

Longitudinal visual and imaging outcomes after intravitreal methotrexate (MTX) for vitreoretinal lymphoma (VRL), and baseline factors associated with remission, remain poorly defined. We evaluated the 12-month efficacy and safety of a reduced-intensity induction regimen followed by response-guided continuation therapy.

Methods

Seventeen consecutive patients with VRL confirmed by vitreous cytology and flow cytometry received intravitreal MTX (400 μg/0.1 mL) at two centers in Bucharest, Romania, between 2018 and 2023. Visual acuity (VA), vitritis and optical coherence tomography (OCT) findings were assessed at baseline and at 1, 3, 6 and 12 months (Friedman and Cochran's Q tests).

Results

Mean VA improved from 1.22 ± 0.70 to 0.74 ± 0.63 logMAR (χ2 = 30.82, p < 0.001; Kendall's W = 0.45), with statistically significant improvement from month 6. At the scheduled 12-month assessment, vitritis and retinal infiltrates had resolved (both unadjusted p < 0.001). Sub-RPE lesions and outer retinal hyperreflectivity decreased (both unadjusted p = 0.031), but these comparisons did not meet the Bonferroni-adjusted significance threshold. Outer retinal disorganization and foveal involvement did not change significantly. Fourteen patients (82.4%) achieved complete ocular remission (median, 6 months); three (17.6%) relapsed and regained disease control after retreatment. Keratopathy was the most frequent adverse event (41.2%); no severe complications occurred.

Conclusions

This regimen was associated with a high ocular remission rate, progressive visual improvement and a manageable safety profile. Because all 10 patients with central nervous system lymphoma also received systemic therapy and/or radiotherapy, ocular outcomes cannot be attributed solely to intravitreal MTX.

Для цитирования: Cioboată Mihai-Luca, Tofolean Ioana, Abduraman Suher, Burcea Radu, Chiotan-Călin Maria-Alexandra, Chiotan Radu-Alexandru, Dăscălescu Dana-Margareta-Cornelia, Cioboată Miruna, Çelebi Ali Rıza Cenk, Baltă Florian. Efficacy and Safety of Response-Adapted Intravitreal Methotrexate Therapy for Vitreoretinal Lymphoma: A Two-Center Retrospective Cohort Study.. Journal of clinical medicine. 2026. DOI: 10.3390/jcm15187323.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.